02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
21:56 , Nov 17, 2016 |  BC Innovations  |  Translation in Brief

Editing hemoglobin

Three independent teams have demonstrated three different ways of using CRISPR to treat sickle cell disease, paving the way for correcting genetic mutations in a disease where the only long-term therapeutic option is blood transplants...
07:00 , Sep 22, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Hemoglobin subunit γ 1 (HBG1); HBG2; CRISPR-associated protein 9 (Cas9)

Hematology INDICATION: Sickle cell disease (SCD) Patient sample and cell culture studies suggest enhancing fetal hemoglobin production in hematopoietic stem and progenitor cells (HSPCs) using CRISPR-based gene editing could help treat SCD. In HSPCs isolated from patients,...